Alain Moussy, founder and chief executive officer, Engineer (ENSTA) and MBA Wharton. He is a former strategic consultant at Booz, Allen & Hamilton and former head of corporate development at Carrefour. President of AFIRMM, association of mastocytosis patients.
Neurodegenerative diseases, taken together, represent a huge unmet medical need. We are determined after this third positive study, this time in Alzheimer’s disease, to continue developing masitinib in consultation with health authorities up to registration, in amyotrophic lateral sclerosis, progressive forms of MS and Alzheimer’s disease.18 February 2021